Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically\* confirmed adenocarcinoma of pancreas~  * Stage I-II disease~ * Resectable disease~* No superior mesenteric vein or artery, portal vein, celiac trunk, or hepatic artery infiltration~* No symptomatic duodenal stenosis~* NOTE: Patients without histological or cytological results may be allowed provided ≥ 1 attempt has been made by needle aspiration with negative imaging and clinical signs suggestive of adenocarcinoma.~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* WBC ≥ 3,500/mm³~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 10 g/dL~* Creatinine ≤ 1.5 mg/dL~* ALT and AST ≤ 3 times upper limit of normal~* Bilirubin ≤ 3 mg/dL~* No prior or concurrent malignancy within the past 5 years except for surgically cured carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin~* Not pregnant or nursing~* No psychological, familial, sociological, or geographical condition that would potentially hinder study compliance or follow-up schedule~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for pancreatic adenocarcinoma~* No other concurrent experimental drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- adjuvant PEXG (Type: EXPERIMENTAL): cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months
- perioperative PEXG (Type: EXPERIMENTAL): cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery
- Adjuvant Gemcitabine (Type: ACTIVE_COMPARATOR): Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).